Une thérapie cellulaire de nouvelle génération, enrichie en interleukine-18, montre une efficacité notable chez des patients atteints de lymphome B réfractaire, déjà traités par CAR-T anti-CD19. Un espoir renouvelé face aux impasses thérapeutiques.

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including commercially available CAR T cell therapies. The new therapy diminished cancer in 81% of patients and resulted in complete remission in 52%, with some of the earliest patients treated experiencing durable remission for two years or more.

L’essor de l’intelligence artificielle, du Big Data, de la blockchain et de la télémédecine ouvre de nouvelles perspectives pour une médecine plus personnalisée, efficace et accessible. La digitalisation n’est plus une option mais une nécessité stratégique pour améliorer l’efficacité des soins.

Keytruda has beaten Roche’s TIGIT drug candidate at the first interim analysis of a phase 2/3 lung cancer trial, prompting the Swiss drugmaker to stop the study and consider changes to the broader program.

GSK is licensing an ABL Bio technology that yields bispecific antibodies engineered to leverage a certain transmembrane receptor to cross the blood-brain barrier to treat neurodegeneration. GSK is already partnered with Alector, which has monoclonal antibodies in clinical development for Alzheimer’s disease.

By moving beyond adherence and drug interactions to a holistic, outcomes-driven approach, health systems and providers can redefine how medication is used — not as a rigid protocol but as a dynamic, patient-centered tool for achieving better health.

Pfizer said a patient dosed with danuglipron developed potential drug-induced liver injury. Pfizer is stopping further work on this program, a move that comes nearly two years after it discontinued development of a different obesity drug due to liver safety signals in a clinical trial.

Robert F. Kennedy Jr.’s rise to become secretary of the Department of Health and Human Services has some concerned that anti-vaccine policies are coming. If the nation’s top public health agency pulls support of vaccination, other healthcare stakeholders will need to step up to fill the vaccine messaging void.

Créée en 2022, DrugOptimal développe une application logicielle à destination des établissements de santé, et en particulier des infirmiers et les pharmaciens, pour mieux prévenir les risques d'incompatibilités physicochimiques médicamenteuses.

The integration of advanced materials into drug delivery systems has become the new normal in pharmaceutical science to address the complexity of modern medicine. These innovations have used technologies such as nanocarriers, hydrogels, and bioresponsive polymers to enable precision, efficiency, and superior therapeutic outcomes. Advanced materials have revolutionized drug delivery by improving upon conventional systems, and their application in various fields, including oncology, chronic disease management, and vaccine delivery, has been remarkable.

Microplastics are everywhere—in our water, food, and even the air we breathe. A new scientific review highlights a growing concern: microplastics and nanoplastics are accumulating in human brain tissue. Researchers are now investigating what this could mean for brain health and how we can reduce our exposure.

Last month, the Japanese pharma deprioritized the development of mezagitamab, also known as TAK-079, in myasthenia gravis and systemic lupus erythematosus as part of a wider pipeline shake-up. But the team said at the time that it was still planning to continue to clinically evaluate the antibody in ITP.

If you rely on federal grants as your sole means of support, you’re tying your destiny to forces outside your control. There are other roads to success in health and medical research. By pursuing them, you might gain more freedom, fewer administrative hurdles, and the chance to save lives faster.

Balancing healthcare benefits and insurance costs requires research. From becoming a Difference Card member to offering wellness resources, there are many ways to improve healthcare at low cost.

For GLP-1 receptor agonists specifically, adherence challenges are a major concern, as these medications require long-term use to achieve meaningful health benefits in chronic conditions like diabetes and obesity.

New research found that most healthcare CFOs anticipate minimal financial gains this year due to high labor costs and insufficient payer rates. While providers are leveraging more data to improve financial planning, persistent challenges like wage pressures, recruiting difficulties and payers' increasing use of technology to deny claims continue to strain margins.

For decades, EMS has relied on blood component therapy, which was favored for its longer shelf life, efficiency, and lower risk of transfusion reactions. However, emerging data suggests that whole blood transfusion in the field could significantly improve survival rates, particularly in rural and remote areas where longer transport times pose additional risks.

AbbVie is licensing rights to a drug from Gubra that has encouraging early clinical data in obesity. The once-weekly injectable peptide is a dual agonist of the amylin and calcitonin receptors, both of which play key roles in metabolism.

Having some belly fat may be beneficial for brain health in younger individuals due to its role in maintaining healthy BDNF. Aging disrupts this benefit because of decreased production of a key protein, CX3CL1. This leads to lower BDNF levels and potentially contributes to cognitive decline. Excessive fat accumulation, particularly in obesity, is associated with overexpression of 11β-HSD1, which is linked to negative metabolic effects.

In the study, the DN gel rapidly reprogrammed differentiated cancer cells into cancer stem cells in just 24 hours in six different human cancer cell lines — brain cancer, uterine cancer, lung cancer, colon cancer, bladder cancer, and sarcoma. After cancer cells were placed on the DN gel, they started to form spherical structures and produce specific molecules known to be markers of cancer stem cells such as SOX2 and Oct3/4, aka Yamanaka factors, named after the Nobel Prize laureate, suggesting they had been reprogrammed.